Histone demethylase inhibitors
AssigneeQuanticel Pharmaceuticals, Inc.
InventorsYoung K. Chen, Michael Brennan Wallace
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Claims34
A compound having the structure of Formula (I),
- or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is hydrogen or alkyl;
- R2 is hydrogen, halogen or alkyl;
- G is
- n is 0, 1, or 2;
- R3 is alkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, or heterocyclylalkyl;
- R4 is halogen, alkyl, alkoxy, carbocyclyl, heterocyclyl, aryl, heteroaryl, or X—R5;
- wherein:
- X is —(C1-C6)alkylene-, —O—, —S—, or —NR1—;
- and
- R5 is carbocyclyl, heterocyclyl, aryl, or heteroaryl.
A pharmaceutical composition comprising a compound of any of the proceeding claims, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
A method for inhibiting a histone demethylase enzyme comprising contacting the histone demethylase enzyme with a compound of any of the proceeding claims.
A method for treating cancer in subject in need thereof comprising administering to the subject a composition comprising a compound of any of the proceeding claims, or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.